您的位置: 首页 > 农业专利 > 详情页

Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
专利权人:
Teva Pharmaceutical Industries Ltd.
发明人:
Tchelet, Amir,Macciardi, Fabio,Levy, Joseph
申请号:
AU2012323345
公开号:
AU2012323345A1
申请日:
2012.10.09
申请国别(地区):
AU
年份:
2014
代理人:
摘要:
Provided is a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a phanmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the step of detenriining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs), identifying the subject as a predicted responder or non-responder to glatiramer acetate based on the determined SNP genotype, and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充